21 related articles for article (PubMed ID: 1159052)
1. Growth hormone/insulin-like growth factor system in children with chronic renal failure.
Tönshoff B; Kiepe D; Ciarmatori S
Pediatr Nephrol; 2005 Mar; 20(3):279-89. PubMed ID: 15692833
[TBL] [Abstract][Full Text] [Related]
2. Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.
Müller EE; Rolla M; Ghigo E; Belliti D; Arvat E; Andreoni A; Torsello A; Locatelli V; Camanni F
Drugs; 1995 Nov; 50(5):805-37. PubMed ID: 8586028
[TBL] [Abstract][Full Text] [Related]
3. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.
Haffner D; Schaefer F; Girard J; Ritz E; Mehls O
J Clin Invest; 1994 Mar; 93(3):1163-71. PubMed ID: 8132756
[TBL] [Abstract][Full Text] [Related]
4. Hypothalamic-pituitary dopaminergic function in hepatic failure in man.
Lal S; Oravec M; Aronoff A; Kiely ME; Guyda H; Solomon S; Nair NP
J Neural Transm; 1982; 53(1):7-21. PubMed ID: 7062015
[TBL] [Abstract][Full Text] [Related]
5. Disturbance of growth hormone--insulin-like growth factor axis in uraemia. Implications for recombinant human growth hormone treatment.
Tönshoff B; Schaefer F; Mehls O
Pediatr Nephrol; 1990 Nov; 4(6):654-62. PubMed ID: 2088470
[TBL] [Abstract][Full Text] [Related]
6. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man.
Sheppard M; Shapiro B; Pimstone B; Kronheim S; Berelowitz M; Gregory M
J Clin Endocrinol Metab; 1979 Jan; 48(1):50-3. PubMed ID: 422706
[TBL] [Abstract][Full Text] [Related]
7. Metabolic clearance and plasma half disappearance time of exogenous gonadotropin releasing hormone in normal subjects and in patients with liver disease and chronic renal failure.
Pimstone B; Epstein S; Hamilton SM; LeRoith D; Hendricks S
J Clin Endocrinol Metab; 1977 Feb; 44(2):356-60. PubMed ID: 320223
[TBL] [Abstract][Full Text] [Related]
8. Marked prolongation in disappearance half-time of plasma cholecystokinin-octapeptide in patients with hepatic cirrhosis.
Kanayama S; Himeno S; Kurokawa M; Shinomura Y; Kuroshima T; Okuno M; Tsuji K; Higashimoto Y; Ikei N; Hashimura E
Am J Gastroenterol; 1985 Jul; 80(7):557-60. PubMed ID: 4014106
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin and serum gastrin in normal subjects and in patients with pernicious anaemia, chronic liver and renal disease.
Le Roith D; Vinik AI; Epstein S; Baron P; Olkenitzky MN; Pimstone BL
S Afr Med J; 1975 Sep; 49(39):1601-4. PubMed ID: 1179234
[TBL] [Abstract][Full Text] [Related]
10. Human growth hormone kinetics in critically ill patients.
Hiesmayr M; Hölzenbein T; Valentini L; Sautner T; Karner J; Roth E
Wien Klin Wochenschr; 1996; 108(12):352-7. PubMed ID: 8767407
[TBL] [Abstract][Full Text] [Related]
11. Disappearance rates of plasma growth hormone after intravenous somatostatin in renal and liver disease.
Pimstone BL; Le Roith D; Epstein S; Kronheim S
J Clin Endocrinol Metab; 1975 Aug; 41(2):392-3. PubMed ID: 1159052
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
